Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Nephrol Ther ; 18(6): 565-569, 2022 Nov.
Article in French | MEDLINE | ID: mdl-35915034

ABSTRACT

INTRODUCTION: Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically. CASE PRESENTATION: We report a case of acute interstitial nephritis to lenalidomide in a 62-year-old patient with multiple myeloma after administration of the second course of chemotherapy according to the protocol combining bortezomib, lenalidomide and dexamethasone. The outcome was quickly favorable after stopping lenalidomide, with corticosteroid therapy. CONCLUSION: Lenalidomide may be responsible for acute interstitial nephritis. When acute kidney injury occurs in myeloma, the nephrotoxicity of therapeutic agents should be considered in addition to the common causes of kidney failure. The chronology of events and the histological data are essential and guide the specific management.


Subject(s)
Acute Kidney Injury , Multiple Myeloma , Nephritis, Interstitial , Humans , Middle Aged , Lenalidomide/adverse effects , Multiple Myeloma/drug therapy , Multiple Myeloma/complications , Multiple Myeloma/pathology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Nephritis, Interstitial/chemically induced , Nephritis, Interstitial/complications , Acute Kidney Injury/etiology
SELECTION OF CITATIONS
SEARCH DETAIL